B-TURP versus HoLEP: Peri-Operative Outcomes and Complications in Frail Elderly (>75 y.o.) Patients: A Prospective Randomized Study
- PMID: 36551968
- PMCID: PMC9776283
- DOI: 10.3390/biomedicines10123212
B-TURP versus HoLEP: Peri-Operative Outcomes and Complications in Frail Elderly (>75 y.o.) Patients: A Prospective Randomized Study
Abstract
Background: The aim of this study was to compare the peri-operative and functional results between trans-urethral resection of the prostate (TURP) and holmium laser enucleation of the prostate (HoLEP) in the treatment of benign prostatic hyperplasia (BPH) associated with lower urinary tract symptoms (LUTS) in middle-old patients. Materials and Methods: This prospective single-center study included patients over 75 years old treated with B-TURP or HoLEP for BPH associated with LUTS with prostate volume (PV) <100 mL. Primary endpoints were the intra-operative blood loss, percentage of loss of hemoglobin, blood transfusion, complications, and the comparison of functional outcomes. All patients were evaluated at 1, 3, 6, and 12 months of follow-up. Results: Overall, 96 patients undergoing HoLEP and 104 B-TURP were eligible and enrolled for the study. Post-operative results showed statistically significant differences between the two groups, all in favor of HoLEP group, specifically in terms of removed prostate tissue, PV reduction rate, hemoglobin values at 24 h, hemoglobin loss, operative time, length of hospitalization, days of catheterization, and urinary flow rates. There was no significant difference in terms of postvoid residual urine volume, perioperative complication, blood transfusion, International Prostate Symptom Score (IPSS), and IPSS quality of life scores. Conclusions: In middle-old patients, the HoLEP technique represents a prostate size-independent treatment option with a more favorable safety profile defined by less bleeding, lower blood transfusions, and a significantly lower hemoglobin drop than B-TURP.
Keywords: HoLEP; TURP; benign prostatic hyperplasia; elderly; lower urinary tract symptoms.
Conflict of interest statement
The authors declare that there are no conflict of interest to disclose.
Figures
Similar articles
-
Holmium Laser Enucleation Versus Bipolar Plasmakinetic Resection for Management of Lower Urinary Tract Symptoms in Patients with Large-Volume Benign Prostatic Hyperplasia: Randomized-Controlled Trial.J Endourol. 2021 Feb;35(2):171-179. doi: 10.1089/end.2020.0636. Epub 2020 Oct 29. J Endourol. 2021. PMID: 32842769 Clinical Trial.
-
Feasibility of holmium laser enucleation of the prostate (HoLEP) for recurrent/residual benign prostatic hyperplasia (BPH).BJU Int. 2012 Dec;110(11 Pt C):E845-50. doi: 10.1111/j.1464-410X.2012.11290.x. Epub 2012 Jun 15. BJU Int. 2012. PMID: 22702908
-
A randomized trial comparing holmium laser enucleation of the prostate with transurethral resection of the prostate for the treatment of bladder outlet obstruction secondary to benign prostatic hyperplasia in large glands (40 to 200 grams).J Urol. 2003 Oct;170(4 Pt 1):1270-4. doi: 10.1097/01.ju.0000086948.55973.00. J Urol. 2003. PMID: 14501739 Clinical Trial.
-
Shifting Trends in Prostate Treatment: A Systematic Review Comparing Transurethral Resection of the Prostate and Holmium Laser Enucleation of the Prostate.Cureus. 2023 Sep 29;15(9):e46173. doi: 10.7759/cureus.46173. eCollection 2023 Sep. Cureus. 2023. PMID: 37905244 Free PMC article. Review.
-
Holmium laser enucleation of the prostate (HoLEP): a review and update.Can J Urol. 2019 Aug;26(4 Suppl 1):13-19. Can J Urol. 2019. PMID: 31481144 Review.
Cited by
-
Functional Outcome and Safety of Endoscopic Treatment Options for Benign Prostatic Obstruction (BPO) in Patients ≥ 75 Years of Age.J Clin Med. 2024 Mar 8;13(6):1561. doi: 10.3390/jcm13061561. J Clin Med. 2024. PMID: 38541787 Free PMC article. Review.
-
Prostatic Artery Embolization in Elderly Comorbid Patients with Benign Prostatic Hyperplasia: Safety, Efficacy, and Predictive Factors of Clinical Failure.J Pers Med. 2025 Jan 10;15(1):23. doi: 10.3390/jpm15010023. J Pers Med. 2025. PMID: 39852215 Free PMC article.
-
Optimizing hemostasis in HoLEP surgery: retrospective review of selective bipolar plasmakinetic technology guided by bladder irrigation fluid color.World J Urol. 2024 Jul 18;42(1):419. doi: 10.1007/s00345-024-05130-x. World J Urol. 2024. PMID: 39023815 Free PMC article.
References
-
- Verhamme K., Dieleman J., Bleumink G., van der Lei J., Sturkenboom M., Panel T.P.E.E. Incidence and prevalence of lower urinary tract symptoms suggestive of benign prostatic hyperplasia in primary care—The triumph project. Eur. Urol. 2002;42:323–328. doi: 10.1016/S0302-2838(02)00354-8. - DOI - PubMed
-
- Gratzke C., Bachmann A., Descazeaud A., Drake M.J., Madersbacher S., Mamoulakis C., Oelke M., Tikkinen K.A., Gravas S. EAU guidelines on the assessment of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction. Eur. Urol. 2015;67:1099–1109. doi: 10.1016/j.eururo.2014.12.038. - DOI - PubMed
-
- Lourenco T., Pickard R., Vale L., Grant A., Fraser C., MacLennan G., N’Dow J. Alternative approaches to endoscopic ablation for benign enlargement of the prostate: Systematic review of randomized controlled trials. BMJ. 2008;337:a449. doi: 10.1136/bmj.39575.517674.BE. - DOI - PMC - PubMed
-
- Salciccia S., Del Giudice F., Maggi M., Eisenberg M.L., Chung B.I., Conti S.L., Kasman A.M., Vilson F.L., Ferro M., Lucarelli G., et al. Safety and Feasibility of Outpatient Surgery in Benign Prostatic Hyperplasia: A Systematic Review and Meta-Analysis. J. Endourol. 2021;35:395–408. doi: 10.1089/end.2020.0538. - DOI - PubMed
-
- Busetto G.M., Del Giudice F., D’Agostino D., Romagnoli D., Minervini A., Rocco B., Antonelli A., Celia A., Schiavina R., Cindolo L., et al. Efficacy and safety of Finasteride (5 alpha-reductase inhibitor) monotherapy in patients with benign prostatic hyperplasia: A critical review of the literature. Arch. Ital. Urol. Androl. 2020;91:205–210. doi: 10.4081/aiua.2019.4.205. - DOI - PubMed
LinkOut - more resources
Full Text Sources